复方苦参注射液联合化疗在晚期卵巢癌中的综合疗效研究

Efficacy of compound oxymatrine injection combination with postoperative chemotherapy for advanced ovarian carcinoma

目的研究复方苦参注射液联合化疗在晚期卵巢癌中的综合疗效。方法将86例晚期卵巢癌患者按随机数字表法分为观察组和对照组，每组43例。观察组采用顺铂＋紫杉醇化疗方案并加复方苦参注射液，对照组仅采用顺铂＋紫杉醇化疗方案。观察两组患者治疗前后白细胞的变化、不良反应及疗效。结果观察组治疗后白细胞明显高于对照组[（4．7±1．4）×10^9／L比（3．2±1．6）×10^9]t，P〈0．05]；观察组恶心呕吐、转氨酶升高、肾功能损害发生率明显低于对照组[16．3％（7／43）、14．0％（6／43）、20．9％（9／43）比34．9％（15／43）、32．6％（14／43）、44．2％（19／43），P〈0．05]；观察组完全缓解率明显高于对照组[55．8％（24／43）比27．9％（12／43），P〈0．05]。结论复方苦参注射液能较好地保护卵巢癌化疗患者的白细胞不下降、减轻化疗的不良反应，提高疗效。

Objective To evaluate the effect of compound oxymatrine injection combination with chemotherapy in patients with advanced ovarian carcinoma. Methods Eighty-six patients with advanced ovarian carcinoma were divided by random digits table method into observation group （43 cases） receiving compound oxymatrine injection plus chemotherapy （paclitaxel plus carboplatin） and control group （43 cases） treated with chemotherapy （paclitaxel plus carboplatin） alone. The change of white blood cell, adverse reaction and effect of the patients were observed. Results The white blood cell of observation group after treatment was obviously higher than that of control group [ （4.7±1.4）×10^9/L vs （3.2±1.6）×10^9]t, P 〈 0.05 ]. The rates of nausea and vomiting, transaminase elevating and kidney damage of observation group were obviously lower than those of control group [ 16.3% （7/43）, 14.0% （6/43）, 20.9% （9/43） vs. 34.9% （ 15/43 ）, 32.6% （ 14/43 ）, 44.2% （ 19/43 ）, P 〈 0.05 ]. The complete remission rate of observation group was significantly higher than that of control group [ 55.8% （24/43） vs. 27.9% （ 12/43 ）, P 〈 0.05 ]. Conclusion Addition of compound oxymatrine injection to chemotherapy for patients with advanced ovarian carcinoma can effectively protect patients against the decreasing of the white blood cell and attenuate the side effects brought by chemotherapy.